W. Lee, Hepatitis B Virus Infection, New England Journal of Medicine, vol.337, issue.24, pp.1733-1778, 1997.
DOI : 10.1056/NEJM199712113372406
URL : https://hal.archives-ouvertes.fr/hal-01260424

D. Lavanchy, Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures, Journal of Viral Hepatitis, vol.34, issue.2, pp.97-107, 2004.
DOI : 10.1056/NEJM200012073432302

G. Lau, T. Piratvisuth, K. Luo, P. Marcellin, S. Thongsawat et al., Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B, New England Journal of Medicine, vol.352, issue.26, pp.2682-95, 2005.
DOI : 10.1056/NEJMoa043470

P. Marcellin, T. Chang, S. Lim, M. Tong, W. Sievert et al., Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen???Positive Chronic Hepatitis B, New England Journal of Medicine, vol.348, issue.9, pp.808-824, 2003.
DOI : 10.1056/NEJMoa020681

N. Leung, C. Lai, T. Chang, R. Guan, C. Lee et al., Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy, Hepatology, vol.33, issue.6, pp.1527-1559, 2001.
DOI : 10.1053/jhep.2001.25084

C. Lai, J. Dienstag, E. Schiff, N. Leung, M. Atkins et al., Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B, Clinical Infectious Diseases, vol.36, issue.6, pp.687-96, 2003.
DOI : 10.1086/368083

M. Melegari, P. Scaglioni, and J. Wands, Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective, Hepatology, vol.22, issue.2, pp.628-661, 1998.
DOI : 10.1002/hep.510270243

D. Wet, H. Yang, C. Westland, K. Das, E. Arnold et al., The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro, J Virol, vol.77, issue.21, pp.11833-11874, 2003.

M. Allen, M. Deslauriers, C. Andrews, G. Tipples, K. Walters et al., Identification and characterization of mutations in hepatitis B virus resistant to lamivudine, Hepatology, vol.15, issue.6, pp.1670-1677, 1998.
DOI : 10.1002/hep.510270628

S. Hadziyannis, N. Tassopoulos, E. Heathcote, T. Chang, G. Kitis et al., Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.352, issue.26, pp.2673-81, 2005.
DOI : 10.1056/NEJMoa042957

S. Locarnini, . Qx, and S. Arterburn, Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB), 40th Annual Meeting of the European Association for the Study of the Liver, 2005.

S. Villet, C. Pichoud, J. Villeneuve, C. Trepo, and F. Zoulim, Selection of a Multiple Drug-Resistant Hepatitis B Virus Strain in a Liver-Transplanted Patient, Gastroenterology, vol.131, issue.4, pp.1253-61, 2006.
DOI : 10.1053/j.gastro.2006.08.013
URL : https://hal.archives-ouvertes.fr/inserm-00133169

J. Villeneuve, D. Durantel, S. Durantel, C. Westland, S. Xiong et al., Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient, Journal of Hepatology, vol.39, issue.6, pp.1085-1094, 2003.
DOI : 10.1016/j.jhep.2003.09.022

P. Angus, R. Vaughan, S. Xiong, H. Yang, W. Delaney et al., Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase, Gastroenterology, vol.125, issue.2, pp.292-299, 2003.
DOI : 10.1016/S0016-5085(03)00939-9

S. Fung, P. Andreone, S. Han, R. Reddy, K. Regev et al., Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation, Journal of Hepatology, vol.43, issue.6
DOI : 10.1016/j.jhep.2005.05.037

C. Osiowy, J. Villeneuve, E. Heathcote, E. Giles, and J. Borlang, Detection of rtN236T and rtA181V/T Mutations Associated with Resistance to Adefovir Dipivoxil in Samples from Patients with Chronic Hepatitis B Virus Infection by the INNO-LiPA HBV DR Line Probe Assay (Version 2), Journal of Clinical Microbiology, vol.44, issue.6, pp.1994-2001, 2006.
DOI : 10.1128/JCM.02477-05

M. Brunelle, A. Jacquard, C. Pichoud, D. Durantel, S. Carrouee-durantel et al., Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir, Hepatology, vol.64, issue.6, pp.1391-1399, 2005.
DOI : 10.1002/hep.20723
URL : https://hal.archives-ouvertes.fr/inserm-00133179

M. Sherman, C. Yurdaydin, J. Sollano, M. Silva, Y. Liaw et al., Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B, Gastroenterology, vol.130, issue.7, pp.2039-2088, 2006.
DOI : 10.1053/j.gastro.2006.04.007

D. Tenney, S. Levine, R. Rose, A. Walsh, S. Weinheimer et al., Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine, Antimicrobial Agents and Chemotherapy, vol.48, issue.9, pp.3498-507, 2004.
DOI : 10.1128/AAC.48.9.3498-3507.2004

T. Chang, R. Gish, S. Hadziyannis, J. Cianciara, M. Rizzetto et al., A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients, Gastroenterology, vol.129, issue.4, pp.1198-209, 2005.
DOI : 10.1053/j.gastro.2005.06.055

L. Stuyver, S. Locarnini, A. Lok, D. Richman, W. Carman et al., Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region, Hepatology, vol.33, issue.3, pp.751-758, 2001.
DOI : 10.1053/jhep.2001.22166

D. Durantel, S. Carrouee-durantel, B. Werle-lapostolle, M. Brunelle, C. Pichoud et al., A new strategy for studyingin vitro the drug susceptibility of clinical isolates of human hepatitis B virus, Hepatology, vol.281, issue.4, pp.855-64, 2004.
DOI : 10.1002/hep.20388

J. Summers, P. Smith, and A. Horwich, Hepadnaviral envelope proteins regulate covalently closed circular DNA amplification, J. Virol, vol.64, pp.2819-2843, 1990.

B. Seigneres, S. Aguesse-germon, C. Pichoud, I. Vuillermoz, C. Jamard et al., Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo, Journal of Hepatology, vol.34, issue.1, pp.114-136, 2001.
DOI : 10.1016/S0168-8278(00)00074-X

H. Yim, M. Hussain, Y. Liu, S. Wong, S. Fung et al., Evolution of multi-drug resistant hepatitis B virus during sequential therapy, Hepatology, vol.42, issue.3, pp.703-715, 2006.
DOI : 10.1002/hep.21290

A. Bartholomeusz, B. Tehan, and D. Chalmers, Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations, Antivir Ther, vol.9, issue.2, pp.149-60, 2004.

K. Das, X. Xiong, H. Yang, C. Westland, C. Gibbs et al., Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC), Journal of Virology, vol.75, issue.10, pp.4771-4780, 2001.
DOI : 10.1128/JVI.75.10.4771-4779.2001

X. Xiong, H. Yang, C. Westland, R. Zou, and C. Gibbs, In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance, Hepatology, vol.90, issue.1, pp.219-243, 2000.
DOI : 10.1002/hep.510310132